Abstracts tagged "COVID-19"

Abstract Number: 1158 • ACR Convergence 2023
Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
Maximiliano Diaz Menindez¹, Megan Sullivan², Benjamin Wang³, Andy Abril³, Vikas Majithia², Ronald Butendieck³, Colleen T. Ball⁴ and Florentina Berianu², ¹Mayo Clinic, Phoenix, AZ, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Jacksonville, Jacksonville, FL
Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…
Abstract Number: 1772 • ACR Convergence 2023
Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Adam Titi¹, Ryan Adyniec², Nat Murren¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin-Madison, Madison, WI
Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…
Abstract Number: 2038 • ACR Convergence 2023
Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients
Minerva Nong¹, Medha Barbhaiya², Jonah Levine³, Vivian Bykerk⁴, Rachel Heise⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Department of Population Health Sciences, Weill Cornell Medicine, New York, NY
Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…
Abstract Number: 2567 • ACR Convergence 2023
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Christoph Berger², Christos Polysopoulos¹, Adrian Ciurea³, Diego Andrey⁴, Tanja Maletic¹, Myriam Riek¹, Almut Scherer¹, Isabell von Loga¹, Judith Safford¹, Kim Lauper⁵, Burkhard Moeller⁶, Nicolas Vuilleumier⁴, Axel Finckh⁷ and Andrea Rubbert-Roth⁸, ¹SCQM Foundation, Zurich, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³University Hospital Zurich, Zürich, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Geneva University Hospitals, Genève, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷HUG, Geneva, Switzerland, ⁸Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…
Abstract Number: 0210 • ACR Convergence 2023
Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors
Hilde Ørbo¹, Asia-Sophia Wolf², Kristin Hammersbøen Bjørlykke³, Sarah E. Josefsson², Guri Solum², Ingrid Fadum Kjønstad⁴, Ingrid Jyssum¹, Ingrid Christensen¹, Anne Therese Tveter¹, Joseph Sexton¹, Grete B. Kro⁵, Gunnveig Grødeland⁶, Tore Kvien¹, Jørgen Jahnsen³, John Torgils Vaage⁷, Espen Haavardsholm¹, Sella Provan⁸, Hassen Kared⁹, Ludvig A. Munthe⁷, Kristin Kaasen Jørgensen³, Silje Watterdal Syversen¹, Siri Mjaaland² and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ⁴National Institute of Public Health, Oslo, Norway, ⁵Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁶Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁷Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Department of Immunology, Oslo University Hospital, Oslo, Norway
Background/Purpose: T cells are critical for control of viral infection with SARS-CoV-2, but knowledge is lacking on cellular immune responses following repeated vaccination and breakthrough…
Abstract Number: 0226 • ACR Convergence 2023
Relationships Among Parameters of Mineral Metabolism and Bone Turnover During Acute COVID-related Hospitalization and Subsequent Follow Up: A Pilot Study
Diego Cabrera¹, Clara Wong², Anna Santoro¹, Christine Simpson¹, Karl Insogna¹, Mary Geda¹, Andrew Cohen¹, Alexandra Hadjuk¹, Lauren Ferrante¹ and Evelyn Hsieh³, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health; Section of Rheumatology, VA Connecticut Healthcare System, Westport, CT
Background/Purpose: Inflammatory conditions can exert direct adverse effects on bone metabolism, via increased bone resorption with inadequate compensatory bone formation. COVID-19 has been associated with…
Abstract Number: 1166 • ACR Convergence 2023
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Emily He¹ and Vaneet Sandhu², ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA
Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…
Abstract Number: 1796 • ACR Convergence 2023
Safety & ImmUnogenicity of COVID-19 VaCcines in SystEmic immunE Mediated Inflammatory Diseases (SUCCEED)
Olga Tsyruk¹, Vinod Chandran², Carol Hitchon³, J. Antonio Avina-Zubieta⁴, Ines Colmegna⁵, Paul R. Fortin⁶, Maggie Larche⁷, Gilles Boire⁸, Luck Lukusa¹, Dawn Bowish⁷, Gilaad G Kaplan⁹, Daniel Pereira¹⁰, Roaya Dayam¹¹, Jennifer LF Lee¹, Elizabeth Turnbull¹, Valeria Valerio¹², Laurie Proulx¹³, Janet Gunderson¹⁴, Anne-Claude Gingras¹¹ and Sasha Bernatsky¹², ¹RI-MUHC, Montreal, QC, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University Health Network, Toronto, ON, Canada, ¹¹Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health, Toronto, ON, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ¹⁴Canadian Arthritis Patient Alliance, Saskatoon, SK, Canada
Background/Purpose: The Canadian government's COVID Immunity Task Force funded SUCCEED to study COVID vaccination responses in immune-mediated inflammatory disease(IMID). We describe how drugs, clinical factors,…
Abstract Number: 2040 • ACR Convergence 2023
Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET)
Angela Chun¹, Abraham Bautista-Castillo², Isabella Osuna¹, Kristiana Nasto¹, Flor Munoz³, Gordon Schutze¹, Sridevi Devaraj¹, Eyal Muscal⁴, Marietta De Guzman⁵, Kristen Sexson Tejtel¹, Ioannis Kakadiaris² and Tiphanie Vogel¹, ¹Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ²Computational Biomedicine Lab University of Houston, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, ⁵Baylor College of Medicine, Houston, TX
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV2infection is a recognized mimic of other inflammatory disorders, including Kawasaki Disease and macrophage activation syndrome. However,…
Abstract Number: 2568 • ACR Convergence 2023
First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients
Michael Chen-Xu¹, Daniel Cooper², Rainer Döffinger², Dr Rachel Jones³ and Rona Smith², ¹Unviersity of Cambridge, Cambridge, United Kingdom, ²University of Cambridge, Cambridge, United Kingdom, ³Addenbrooke's Hospital, Cambridge, United Kingdom
Background/Purpose: Primary systemic vasculitis (PSV) patients on immunosuppression are at higher risk of adverse outcomes following COVID-19 infection and often mount suboptimal vaccine responses to…
Abstract Number: 0211 • ACR Convergence 2023
COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study
Hilde Ørbo¹, Ingrid Jyssum¹, Joseph Sexton¹, Anne Therese Tveter¹, Ingrid Christensen¹, Kristin Hammersbøen Bjørlykke², Grete B. Kro³, Tore Kvien¹, Ludvig A. Munthe⁴, Gunnveig Grødeland⁵, Siri Mjaaland⁶, Espen Haavardsholm¹, John Torgils Vaage⁴, Kristin Kaasen Jørgensen², Sella Provan⁷, Silje Watterdal Syversen¹ and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁵Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁶Norwegian Institute of Public Health, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated vaccine responses and are prone to severe infections. Knowledge of COVID-19 outcome following…
Abstract Number: 0227 • ACR Convergence 2023
Associations of DMARDs with Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases: A Prospective Study
Rathnam Venkat¹, Xiaosong Wang², Naomi Patel³, Yumeko Kawano², Abigail Schiff², Emily Kowalski², Claire Cook³, Kathleen Vanni², Grace Qian², Katarina Bade⁴, Alene Saavedra², Shruthi Srivatsan³, Zachary Williams³, Zachary Wallace⁵ and Jeffrey Sparks⁶, ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Post-acute sequelae of COVID-19 (PASC, or "long COVID") is defined by the CDC as COVID-19 symptoms persisting for ≥28 days after infection. Patients with…
Abstract Number: 1203 • ACR Convergence 2023
Vaccination Against SARS-CoV-2 in Inflammatory Arthritis and Factors Determining Its Decision
Olivier FAKIH¹, Charlotte Bourgoin², Violette Benier¹, Thomas Lohse¹, Cerise Guillochon¹, Elodie Bouvier², Jean-Charles Balblanc¹, Thierry Conrozier¹ and Anne Lohse¹, ¹Service de rhumatologie, Hôpital Nord Franche-Comté, Trévenans, France, ²Unité de recherche clinique, Hôpital Nord Franche-Comté, Trévenans, France
Background/Purpose: DMARDs, which are essential for controlling the progression of inflammatory arthritis (IA), are mostly immunomodulators that significantly increase the risk of severe infections. Therefore,…
Abstract Number: 1800 • ACR Convergence 2023
Factors Associated with an Electronic Health Record-Based Definition of Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
Naomi Patel¹, Xiaosong Wang², Yumeko Kawano², Abigail Schiff², Rathnam Venkat², Claire Cook¹, Kathleen Vanni², Grace Qian², Katarina Bade², Shruthi Srivatsan¹, Krishan Guzzo¹, Zachary Williams¹, Emily Kowalski², Alene Saavedra², Jeffrey Sparks³ and Zachary Wallace⁴, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Immunosuppression for treatment of systemic autoimmune rheumatic diseases (SARDs) is associated with increased risk of severe acute COVID-19 due to blunted vaccine responses and…
Abstract Number: 2047 • ACR Convergence 2023
Safety of Baricitinib for COVID-19 Related Hyperinflammation in Pediatric Patients: A Large Tertiary Care Center Experience
Meredith Rae¹, Jessica Nguyen², Marietta DeGuzman³, Catherine Foster¹, Flor Munoz¹ and Eyal Muscal⁴, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Manvel, TX, ³Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: A small proportion of children with acute COVID-19 experienced life-threatening hyperinflammation. It has been proposed that an innate immune recognition of viral RNA triggers…

« Previous Page
1
…
8
9
10
11
12
…
40
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].